Expanding access to medical abortion

Challenges and Opportunities

Dados Bibliográficos

ID3972246
AutoresBela Ganatra (0000-0002-4812-4577, World Bank), Philip Guest (Bangkok University), Marge Berer (0000-0001-6139-497X)
Ano2014
Volume22
Fascículosup44
Páginas1-3
Data de publicação2014-12-01
Peer ReviewedSim
Open AccessNão
TipoARTICLE
PeriódicoReproductive Health Matters (JOURNAL)
Identificadores do periódicoISSN: 0968-8080 • E-ISSN: 1460-9576
EditoraInforma UK Limited (PUBLISHER • GB)
DOI10.1016/s0968-8080(14)43793-5
PMID25702063
OpenAlexW2130551852
IdiomaEN
Citações recebidas4
Referências citadas1

Medical abortion using mifepristone and misoprostol (or misoprostol alone in settings where mifepristone has not yet been approved or made available) is a safe and effective method of terminating both early and later pregnancies. Misoprostol tablets can also be used to manage incomplete abortion and miscarriage. When used in early pregnancy, medical abortion can be provided at a primary care facility and by nonphysician providers. 1 The over three decades long experience with these medications has also provided incremental evidence that many components of early medical abortion can safely take place outside of a facility setting as well, starting with women taking the mifepristone in the clinic and using the misoprostol at home, then also allowing the mifepristone to be taken at home. There are now various efforts going into helping women to check if the pregnancy is complete from home too, as the papers in this supplement show. As the evidence has accumulated, it is also reshaping our understanding and interpretation of the World Health Organization (WHO) definition of unsafe abortion, to account for the fact that “the persons, skills and medical standards considered safe in the provision of abortion are dif

Abortion · Medical abortion · Misoprostol · Political science · Pregnancy · Maternal and Perinatal Health Interventions · Medicine · Reproductive Health and Contraception